Granite Investment Advisors’s Cytokinetics CYTK Stock Holding History

Granite Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,500	Closed	-$384K	–	190
2021 Q1	$384K	Hold	16,500	–	–	0.06%	141
2020 Q4	$343K	Sell	16,500 -1,000	-6%	-$18.3K	0.06%	144
2020 Q3	$379K	Hold	17,500	–	–	0.07%	135
2020 Q2	$412K	Buy	17,500 +2,500	+17%	+$46.9K	0.09%	121
2020 Q1	$177K	Sell	15,000 -2,500	-14%	-$31.9K	0.04%	141
2019 Q4	$186K	Sell	17,500 -1,000	-5%	-$10.3K	0.04%	165
2019 Q3	$211K	Hold	18,500	–	–	0.04%	160
2019 Q2	$208K	Hold	18,500	–	–	0.04%	158
2019 Q1	$150K	Hold	18,500	–	–	0.03%	153
2018 Q4	$117K	Hold	18,500	–	–	0.02%	153
2018 Q3	$182K	Hold	18,500	–	–	0.03%	160
2018 Q2	$154K	Hold	18,500	–	–	0.03%	164
2018 Q1	$133K	Hold	18,500	–	–	0.02%	170
2017 Q4	$151K	Buy	+18,500	New	+$210K	0.03%	177

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Granite Investment Advisors's CYTK Position: Q2 2021 in Review

Granite Investment Advisors sold out of Cytokinetics (CYTK) in Q2 2021, closing a stake of 16,500 shares — an estimated $384K sold.

Granite Investment Advisors first reported a position in CYTK in Q4 2017 and held it in 14 quarters. The position peaked at $412K in Q2 2020. 190 funds tracked by Wall St. Rank hold CYTK as of Q2 2021.

Granite Investment Advisors reported no remaining Cytokinetics position as of Q2 2021 after selling out during the quarter.
Granite Investment Advisors sold 16,500 Cytokinetics shares in Q2 2021, an estimated $384K.
Granite Investment Advisors first reported a position in Cytokinetics in Q4 2017 and held it in 14 quarters.
Granite Investment Advisors's Cytokinetics position peaked at $412K in Q2 2020.
190 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2021.

Based on Granite Investment Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.